Latest Update — As of September 19, 2026, no consolidation order or settlement has been confirmed for the Repatha side-effects litigation described in this article. Individual failure-to-warn and product liability claims against Amgen remain in the pre-filing and case-evaluation stage, with attorneys still building case inventories ahead of any formal MDL petition.
Separately, Amgen has faced patent and antitrust litigation with Sanofi and Regeneron over Repatha and Praluent — including an apparent March 2026 settlement of their patent dispute — but that litigation concerns intellectual property and market competition, not patient injury claims, and does not affect eligibility or settlement value for injured patients.
Last updated: September 2026
Patients who took Repatha and suffered serious side effects have real legal options in 2026. The repatha lawsuit targets Amgen, the drug’s manufacturer, over claims that the company failed to adequately warn patients about dangerous reactions including muscle breakdown, cognitive decline, and liver injury.
This is not a small-time dispute. Repatha generated billions in global sales, and thousands of patients say they were harmed while Amgen stayed quiet about the risks.
In this article, you’ll find exactly what the lawsuits allege, who can file, what settlements might look like, and how deadlines in 2026 affect your ability to recover compensation.
One fact stands out: some patients reported permanent muscle damage after using Repatha for as little as three to six months.
Repatha Lawsuit 2026: What Is Happening Right Now
In 2026, litigation against Amgen over Repatha is accelerating. Plaintiffs across the country are filing individual injury claims, and attorneys are actively building case inventories for potential consolidation.
The core of the 2026 activity centers on failure-to-warn claims. Plaintiffs argue Amgen knew about serious risks and did not update its label warnings promptly or clearly enough.
Federal courts have seen increased filings since late 2024. Legal experts watching the docket expect formal MDL consolidation discussions to intensify through 2026.
| 2026 Litigation Snapshot | Details |
|---|---|
| Primary Allegation | Failure to warn patients of serious side effects |
| Drug Manufacturer | Amgen Inc. |
| Drug Name | Repatha (evolocumab) |
| Claim Types | Personal injury, product liability |
| Litigation Stage | Active filing, pre-MDL consolidation discussions |
| Filing Deadline Window | Varies by state; 2 to 3 years from injury discovery |
The window to act is open right now. Waiting shrinks your options.
What Is the Repatha Lawsuit Actually About
The Repatha lawsuit is about one central accusation: Amgen sold a drug that caused serious physical harm and did not give patients or doctors enough warning to make informed decisions.
Repatha is a PCSK9 inhibitor, meaning it blocks a protein in the liver to lower LDL cholesterol. It was approved by the FDA in 2015 as an injectable alternative for patients who could not tolerate statins or needed extra LDL reduction.
Plaintiffs say the drug’s label understated the risk of muscle injury, cognitive impairment, and other organ damage. That gap between what the label said and what patients experienced is the legal engine driving these cases.
- Core legal theories in the Repatha lawsuit:
- Failure to warn (inadequate labeling)
- Negligent design or testing
- Misrepresentation of safety profile
- Breach of implied warranty of merchantability
Think of it like buying a car that a manufacturer knew had faulty brakes but only mentioned it in fine print buried in the manual. That is essentially what plaintiffs claim happened here.
Amgen Repatha Lawsuit: The Company Behind the Drug
Amgen Inc. is a California-based pharmaceutical giant and one of the largest biotechnology companies in the world. Repatha is one of its flagship cardiovascular drugs, approved in 2015 by the FDA under the brand name evolocumab.
Amgen marketed Repatha aggressively to patients with high LDL cholesterol, particularly those at high cardiovascular risk who could not control their levels with statins alone. Sales reached over $1 billion annually at peak.
The amgen repatha lawsuit claims the company prioritized market share over patient safety. Plaintiffs point to internal communications, post-market surveillance data, and FDA correspondence as potential evidence that risks were known earlier than publicly acknowledged.
| Amgen Key Facts | Information |
|---|---|
| Headquarters | Thousand Oaks, California |
| FDA Approval Date | August 27, 2015 |
| Drug Classification | PCSK9 inhibitor (biologic) |
| Annual Repatha Revenue (peak) | Over $1 billion globally |
| Primary Allegation Against Amgen | Failure to warn, product liability |
Amgen has denied wrongdoing in public statements. That denial is exactly what the courts are being asked to evaluate.
Key Takeaway: The Repatha lawsuit is a product liability action against Amgen, alleging the company failed to warn patients about serious side effects from a cholesterol drug that earned billions in revenue.
Repatha Side Effects That Triggered Legal Action
The repatha side effects lawsuit is driven by patients who experienced far more than the mild reactions listed in early drug advertising. The most serious reported effects are the foundation for every legal claim filed.
Side effects that have been documented in medical literature and patient reports include a wide range of physical and neurological conditions. Not all are equally common, but all have been associated with evolocumab use in published studies and adverse event reports submitted to the FDA.
- Documented serious side effects linked to Repatha:
- Muscle pain, weakness, and breakdown (myopathy and rhabdomyolysis)
- Memory loss and cognitive impairment
- Elevated liver enzymes and liver injury
- Injection site reactions (severe cases)
- Flu-like symptoms (persistent and debilitating)
- Cardiovascular complications in some patient subgroups
- Neurocognitive disturbances including confusion and difficulty concentrating
The FDA’s Adverse Event Reporting System (FAERS) database contains thousands of reports connected to evolocumab. Plaintiffs use these reports as part of their evidence packages.
Key stat: A 2017 study published in a peer-reviewed cardiology journal found that some PCSK9 inhibitor patients reported measurable cognitive decline, prompting FDA scrutiny of the entire drug class.
Repatha Muscle Damage Lawsuit: What Patients Are Claiming
The repatha muscle damage lawsuit represents some of the most medically severe claims in this litigation. Muscle-related injuries range from moderate myopathy to the life-threatening condition known as rhabdomyolysis.
Rhabdomyolysis is when muscle fibers break down and release a protein called myoglobin into the bloodstream. That protein can overwhelm the kidneys, causing acute kidney injury. Some patients have required hospitalization and dialysis.
Plaintiffs in muscle damage cases allege Amgen knew PCSK9 inhibitors carried muscle risks similar to statins but failed to communicate this adequately. Since many Repatha patients switched from statins specifically because of muscle problems, they say they were blindsided.
| Muscle Injury Type | Description | Severity Level |
|---|---|---|
| Myalgia | Muscle aches and pain | Mild to moderate |
| Myopathy | Muscle weakness with enzyme elevation | Moderate to severe |
| Rhabdomyolysis | Muscle cell breakdown, kidney risk | Severe, potentially fatal |
| Chronic Myopathy | Long-term weakness post-treatment | Severe, may be permanent |
Patients with documented creatine kinase (CK) elevation in bloodwork have stronger legal claims, since that lab marker is objective evidence of muscle damage.
Repatha Cognitive Side Effects Lawsuit: Memory and Mental Decline Claims
The repatha cognitive side effects lawsuit is one of the more unusual aspects of this litigation, and one that caught the FDA’s attention. Patients reported memory problems, confusion, and difficulty concentrating while taking evolocumab.
In 2017, the FDA issued a safety communication noting that some patients taking PCSK9 inhibitors had reported neurocognitive side effects. The agency noted the reports were serious enough to warrant a label update across the drug class.
That FDA communication is legally significant. It shows regulators identified a problem, which supports plaintiff arguments that Amgen should have warned patients earlier and more clearly.
- Cognitive symptoms reported by Repatha patients:
- Short-term memory loss
- Difficulty finding words or concentrating
- Mental fog and confusion
- Personality changes (reported by family members)
- Disorientation in familiar environments
Bold callout: The FDA added a class-wide neurocognitive warning for PCSK9 inhibitors in 2017. Patients who experienced cognitive decline before or after that date may have different legal arguments based on the warning timeline.
For patients whose careers or daily lives were disrupted by cognitive impairment, damages in these cases can be substantial.
Repatha Liver Damage Lawsuit: What the Evidence Shows
The repatha liver damage lawsuit claims that evolocumab caused dangerous elevations in liver enzymes in some patients, a sign of hepatotoxicity or liver cell injury.
Liver enzyme tests (specifically ALT and AST) are standard markers doctors use to detect liver stress. Some patients on Repatha reported abnormal results on routine bloodwork. Others experienced symptomatic liver problems including jaundice, fatigue, and abdominal discomfort.
The liver damage claims are typically supported by before-and-after bloodwork records, medical notes, and specialist evaluations. Patients who have these records are in a stronger position when filing.
| Liver Damage Indicator | What It Means |
|---|---|
| Elevated ALT | Possible liver cell injury |
| Elevated AST | Liver stress or muscle involvement |
| Jaundice | Visible sign of liver dysfunction |
| Bilirubin elevation | Potential bile duct or liver problem |
| Liver biopsy findings | Objective evidence of tissue damage |
Not every patient with elevated enzymes will have a strong case. The legal question is whether Amgen’s inadequate warning denied patients the chance to stop the drug before damage became serious.
Key Takeaway: Repatha lawsuits cover a wide range of serious injuries including muscle breakdown, cognitive decline, and liver damage, each supported by clinical markers that become key evidence in court.
Repatha Stroke and Heart Events Lawsuit: Cardiovascular Claims Explained
The repatha stroke and heart events lawsuit is perhaps the most counterintuitive part of this litigation. Repatha was designed to prevent heart attacks and strokes, so patients who suffered cardiovascular events while on the drug have a complex but potentially powerful claim.
Plaintiffs in these cases argue one of two things. Some say the drug failed to deliver on its promised cardiovascular protection, causing them to forgo more effective treatments. Others claim the drug actually contributed to or triggered cardiovascular events through inflammatory or vascular mechanisms.
The scientific debate here is ongoing. But legally, the key question is not whether the drug causes strokes. The key question is whether patients received accurate information to make an informed choice.
- Cardiovascular claims in Repatha litigation include:
- Stroke events while on evolocumab therapy
- Myocardial infarction despite drug use
- Peripheral artery complications
- Claims of inadequate cardiovascular benefit disclosure
- Wrongful death claims filed by surviving family members
Wrongful death cases carry some of the highest potential damages in pharmaceutical litigation. If a family member died from a stroke or heart attack while on Repatha, survivors may have standing to sue.
Who Qualifies for the Repatha Lawsuit
You may qualify for the Repatha lawsuit if you were prescribed evolocumab, took the drug as directed, and suffered a serious adverse reaction that required medical treatment.
Qualification is not limited to one injury type. Patients with muscle damage, cognitive problems, liver issues, or cardiovascular complications can all potentially file. The severity and documentation of the injury matter significantly.
- General qualification indicators:
- You were prescribed Repatha (evolocumab) by a licensed physician
- You took the drug and experienced serious physical, neurological, or organ-related harm
- Your injury required medical attention, hospitalization, or specialist treatment
- Your harm occurred within the statute of limitations window for your state
- You have medical records, bloodwork, or pharmacy records to support your claim
Quick Facts:
| Qualification Factor | Required |
|---|---|
| Repatha prescription record | Yes |
| Documented medical injury | Yes |
| Treatment or hospitalization | Strongly preferred |
| Specific injury type | Multiple types qualify |
| Geographic location | U.S. patients primarily |
Family members of deceased patients may also qualify if death occurred as a result of a Repatha-related complication.
Repatha Lawsuit Eligibility Criteria: A Detailed Breakdown
Repatha lawsuit eligibility goes beyond simply having taken the drug. Courts and attorneys evaluate claims based on a specific set of factors that determine both qualification and potential compensation value.
The strongest cases combine clear medical documentation, a significant injury, and a timeline that shows the harm occurred while taking the drug. Weak cases often lack records, have minor injuries, or fall outside the statute of limitations.
| Eligibility Factor | Strong Claim | Weak Claim |
|---|---|---|
| Medical records | Detailed records available | No records or lost |
| Injury severity | Hospitalization, permanent harm | Mild, self-resolving |
| Timeline | Injury during or shortly after use | Unconnected timeline |
| Prior conditions | Repatha identified as likely cause | Multiple confounding conditions |
| Duration of use | Several months or longer | Only a few doses |
| Statute of limitations | Within window | Potentially expired |
Pre-existing conditions like diabetes or prior statin use don’t automatically disqualify a claim. Attorneys look at whether Repatha was a contributing factor, not necessarily the sole cause.
Key Takeaway: Eligibility hinges on documented injury, a clear link to Repatha use, and filing within the statute of limitations, making medical records the single most important asset in any claim.
Repatha Class Action vs. Personal Injury Claim: Which Path Is Right for You
A repatha class action and a personal injury claim are very different legal vehicles, and choosing the wrong one can significantly affect your payout.
A class action groups hundreds or thousands of plaintiffs together and results in a shared settlement. Individual payouts tend to be smaller, but the process is simpler. A personal injury claim is filed individually and can yield much higher compensation, but requires more time and legal effort.
For Repatha, most serious injury cases are being filed as individual personal injury or mass tort claims rather than class actions. That is because injuries vary dramatically from patient to patient, making individual claims more appropriate and more valuable.
| Feature | Class Action | Personal Injury / Mass Tort |
|---|---|---|
| Filing type | Group | Individual |
| Average payout | Lower (shared pool) | Higher (based on your harm) |
| Time to resolve | Often faster | Can take years |
| Legal effort | Low (you’re one of many) | Higher (your case is specific) |
| Best for | Minor, similar injuries | Serious, documented harm |
| Current Repatha path | Less common | Primary litigation approach |
If your injury was severe, a personal injury claim almost certainly puts more money in your pocket than joining a class.
Repatha Lawsuit Settlement Amount 2026: What Compensation Could Look Like
No official Repatha lawsuit settlement has been announced as of early 2026, but that does not mean there is nothing to estimate. Similar pharmaceutical product liability cases provide a realistic range.
Mass tort pharmaceutical settlements in comparable drug cases have ranged from tens of thousands of dollars for moderate injuries to several hundred thousand dollars or more for severe, permanent harm. Wrongful death cases involving negligent drug marketing have sometimes resulted in seven-figure settlements.
| Injury Severity | Estimated Settlement Range (Based on Comparable Cases) |
|---|---|
| Mild injury, full recovery | $10,000 to $50,000 |
| Moderate injury, some permanent effects | $50,000 to $150,000 |
| Severe injury, hospitalization | $150,000 to $400,000 |
| Permanent disability or organ damage | $400,000 to $1,000,000+ |
| Wrongful death | $500,000 to $2,000,000+ |
These figures are not guarantees. They reflect precedent from similar pharmaceutical litigation and serve as a framework for understanding what is at stake.
Amgen is a company with deep resources. That financial position means settlements, when reached, can be substantial.
Repatha Lawsuit Payout by Injury Type: How Awards Are Calculated
The repatha lawsuit payout you might receive depends on a specific formula that courts and attorneys use when evaluating pharmaceutical injury claims. It is not guesswork. It is built on categories.
Compensation in these cases typically breaks down into economic damages (things with a dollar amount like medical bills and lost wages) and non-economic damages (things without a fixed price like pain, suffering, and loss of quality of life). Punitive damages may apply if Amgen’s conduct is found to be especially reckless.
- Compensation categories in Repatha cases:
- Medical expenses: All past and future costs related to the injury, including hospitalization, specialist care, and rehabilitation
- Lost wages: Income lost during recovery, including future earning capacity if the injury is permanent
- Pain and suffering: Physical discomfort, emotional distress, and mental anguish
- Loss of enjoyment of life: Inability to perform activities you once could
- Punitive damages: Additional money meant to punish Amgen if gross negligence is proven
Cognitive impairment cases can generate large non-economic damage awards because the loss of mental function is profoundly life-altering and juries tend to respond to it emotionally.
Key Takeaway: Repatha lawsuit payouts are calculated across medical costs, lost wages, pain and suffering, and potentially punitive damages, with severe or permanent injuries commanding the highest awards.
Repatha MDL and Litigation Status: Where the Cases Stand
An MDL, or Multidistrict Litigation, is a federal process that consolidates cases from across the country into one court for pre-trial proceedings. It is the most common structure for large pharmaceutical lawsuits.
As of 2026, attorneys and plaintiff firms are building case inventories and evaluating whether a formal MDL petition will be filed. The volume of Repatha-related injury reports supports the argument that consolidation makes sense.
MDL consolidation does not mean cases are merged permanently. Each plaintiff still has their own individual case. The MDL simply allows pre-trial discovery, expert witness development, and motions to be handled more efficiently.
| MDL Phase | What Happens |
|---|---|
| Case filing | Individual plaintiffs file in federal court |
| MDL petition | Attorneys seek consolidation before MDL panel |
| Consolidation | Cases moved to one federal district |
| Discovery | Evidence gathering, depositions, expert witnesses |
| Bellwether trials | A few cases tried first to guide settlement value |
| Global settlement | Compensation offered to all qualified plaintiffs |
Bellwether trial results are the moment that usually forces pharmaceutical companies to settle. Early verdicts create pricing for the entire inventory of cases.
How to File a Repatha Lawsuit: Step-by-Step
Filing a repatha lawsuit is a structured process. It begins with gathering your evidence and ends with either a settlement or trial, though most pharmaceutical cases settle before reaching a jury.
The process is not something most people navigate alone. Mass tort law firms handle these cases on a contingency basis, meaning you pay nothing unless you win. That makes legal representation accessible regardless of your financial situation.
- Steps to file a Repatha lawsuit in 2026:
- Collect your medical records: Gather all records showing your Repatha prescription, dosage, treatment duration, and any documented side effects or hospitalizations
- Gather pharmacy records: Proof of purchase and fill history from your pharmacy supports your timeline
- Document your injury: Bloodwork, specialist notes, imaging, and any written records of symptoms strengthen your claim
- Contact a mass tort attorney: Repatha cases are handled by personal injury attorneys experienced in pharmaceutical litigation
- Case evaluation: The attorney reviews your records and determines whether you have a viable claim
- Complaint filed: If the case moves forward, a legal complaint is filed in the appropriate court
- Discovery and negotiation: Both sides gather evidence; settlement discussions typically begin during this phase
- Resolution: Cases are resolved through settlement or, less commonly, trial
The entire process from filing to resolution in pharmaceutical mass torts often takes two to four years, though settlement timelines vary.
Repatha Lawsuit Claim Deadline 2026: Do Not Miss This Window
The repatha lawsuit claim deadline is governed by each state’s statute of limitations, and in 2026, some patients are approaching or have already passed their filing window.
Most states allow two to three years from the date of injury discovery to file a personal injury lawsuit. The discovery rule is key here. The clock starts when you knew or reasonably should have known that Repatha caused your injury, not necessarily when you first took the drug.
| State Statute of Limitations (General) | Time Limit |
|---|---|
| California | 2 years from discovery |
| Texas | 2 years from discovery |
| New York | 3 years from discovery |
| Florida | 2 years from discovery |
| Illinois | 2 years from discovery |
| Ohio | 2 years from discovery |
Critical point: Waiting even a few months can cost you your right to file. If you believe Repatha harmed you, the safest move is to seek a case evaluation now rather than assuming you have more time.
Wrongful death statutes of limitations are separate and often shorter. Family members of deceased patients should treat the timeline as even more urgent.
Key Takeaway: The 2026 filing window is open, but it is shrinking for many patients, especially those injured in 2023 or early 2024, making timely action the single most important step right now.
Frequently Asked Questions
Is there an active Repatha lawsuit in 2026?
Yes, Repatha lawsuits are actively being filed in 2026.
Individual personal injury and product liability claims against Amgen are moving through federal courts, with attorneys preparing for potential MDL consolidation.
The primary allegation is that Amgen failed to adequately warn patients about serious side effects including muscle damage, cognitive decline, and liver injury.
How much money can I get from a Repatha lawsuit settlement?
Settlement amounts depend on the severity and permanence of your injury.
Based on comparable pharmaceutical mass tort cases, moderate injuries have settled in the $50,000 to $150,000 range, while severe or permanent harm has reached $400,000 or more.
No official Repatha settlement fund has been established as of early 2026, but case values are expected to align with this range once litigation matures.
What side effects qualify someone for the Repatha lawsuit?
Serious side effects that have required medical attention are the primary basis for qualifying.
These include muscle breakdown (myopathy or rhabdomyolysis), memory loss or cognitive impairment, elevated liver enzymes or liver injury, and cardiovascular complications.
Minor side effects that resolved on their own are generally not sufficient to support a strong claim.
How long do I have to file a Repatha lawsuit in 2026?
Most states give you two to three years from the date you discovered your injury to file.
The discovery rule means the clock starts when you knew or should have known Repatha was responsible, not simply when you stopped taking the drug.
If your injury became apparent in 2022 or 2023, your window may be closing and should be evaluated immediately.
Can I join a Repatha class action or do I need to file individually?
Repatha cases are primarily being handled as individual personal injury or mass tort claims rather than class actions.
Individual claims typically result in higher payouts because compensation is tied directly to the severity of your specific injury.
A mass tort attorney can evaluate whether your case is better suited to individual filing or a consolidated group action depending on your circumstances.
The Bottom Line on Repatha Lawsuits in 2026
Repatha patients who suffered real harm have real legal options. The litigation against Amgen is active, case inventories are growing, and the factual foundation for these lawsuits is supported by FDA safety communications and years of adverse event reports.
Your medical records are the most important thing you can gather right now. They are your evidence. They are your leverage.
If you took Repatha and experienced serious muscle problems, cognitive changes, liver issues, or a cardiovascular event, the time to explore your legal options is before the statute of limitations closes your window for good.
